Compare ORC & OPK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ORC | OPK |
|---|---|---|
| Founded | 2010 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 2013 | 1995 |
| Metric | ORC | OPK |
|---|---|---|
| Price | $7.21 | $1.26 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $7.50 | $2.28 |
| AVG Volume (30 Days) | ★ 6.0M | 3.7M |
| Earning Date | 01-29-2026 | 10-29-2025 |
| Dividend Yield | ★ 20.00% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | $80,187,000.00 | ★ $642,067,000.00 |
| Revenue This Year | $90.64 | N/A |
| Revenue Next Year | $78.88 | N/A |
| P/E Ratio | $12.55 | ★ N/A |
| Revenue Growth | ★ 5.93 | N/A |
| 52 Week Low | $5.69 | $1.11 |
| 52 Week High | $9.01 | $2.04 |
| Indicator | ORC | OPK |
|---|---|---|
| Relative Strength Index (RSI) | 45.63 | 36.18 |
| Support Level | $7.28 | $1.29 |
| Resistance Level | $7.40 | $1.34 |
| Average True Range (ATR) | 0.12 | 0.05 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 27.72 | 5.91 |
Orchid Island Capital Inc is a specialty finance company that invests in residential mortgage-backed securities. The principal and interest payments of its RMBS are guaranteed by the Federal National Mortgage Association, the Federal Home Loan Mortgage Corporation, or the Government National Mortgage Association, and are backed by single-family residential mortgage loans. The company's investment portfolio is divided into two categories namely traditional pass-through Agency RMBS; and structured Agency RMBS, such as collateralized mortgage obligations, interest-only securities, inverse interest-only securities, and principal-only securities, among other types of structured Agency RMBS.
OPKO Health Inc is a diversified biotechnology company that operates pharmaceutical and diagnostic development programs. Its segments include pharmaceutical and diagnostics. The Pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its pharmaceutical research and development operations. The Diagnostics segment consists of clinical and genomics laboratory operations through BioReference and point-of-care operations. It generates the majority of its revenue from the Diagnostics segment.